skip to the content

Clinical Trials

Breast Cancer Study

NSABP-B43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy

Protocol ID

08-307

Protocol Description

This study is being done to compare the effects, good and/or bad, of adding the drug trastuzumab (also called Herceptin®) to breast radiation therapy.  Radiation therapy is the standard treatment for patients with a very early stage of breast cancer called ductal carcinoma in situ (DCIS). This study will find out if adding trastuzumab to breast radiation therapy is more effective than radiation therapy without trastuzumab in preventing occurrence of breast cancer in the same breast, in the other breast, or in other parts of the body in patients with HER2-positive DCIS.
The drug trastuzumab is called a targeted therapy because it targets breast cancers that make too much of a protein called HER2.  These cancers are called HER2-positive.  Too much of the HER2 protein can cause cells to receive extra growth signals.  This can turn a normal cell into a cancer cell and can cause cancer cells to grow faster.
Trastuzumab has been shown to block the HER2 protein and to slow down or stop the growth of HER2-positive “invasive” breast cancers.

Eligibility Criteria

Patients with breast cancer

Primary Investigator(s)

  • Lora Weiselberg, MD

Contact Information

Doreen Mayberry, RN
(516) 734-8916
dmayberr@nshs.edu

Last Update

July 12, 2011
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Cancer:
top
top